The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I/II study of the selective PI3Kβ inhibitor GSK2636771 in combination with pembrolizumab in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and PTEN loss.
 
Ecaterina Elena Dumbrava
Consulting or Advisory Role - Bolt Biotherapeutics
Research Funding - Aileron Therapeutics (Inst); Amgen (Inst); Aprea Therapeutics (Inst); Astex Pharmaceuticals (Inst); Bayer (Inst); Bellicum Pharmaceuticals (Inst); Bolt Biotherapeutics (Inst); Compugen (Inst); Gateway Foundation (Inst); Immunocore (Inst); Immunomedics/Gilead (Inst); Mereo BioPharma 5 (Inst); PMV Pharma (Inst); Rain Therapeutics (Inst); Sanofi (Inst); Seagen (Inst); TRACON Pharma (Inst); Triumvira Immunologics, Inc (Inst); Unum Therapeutics (Inst)
 
Elizabeth M. Burton
No Relationships to Disclose
 
Sumit Kumar Subudhi
Stock and Other Ownership Interests - Apricity Health
Honoraria - Amgen; Apricity Health; AstraZeneca; Bayer; Bristol-Myers Squibb; Dava Oncology; Dendreon; Exelixis; Janssen; Parker Institute for Cancer Immunotherapy; Polaris; Society for Immunotherapy of Cancer
Consulting or Advisory Role - Amgen; Apricity Health; AstraZeneca; Bayer; Bristol-Myers Squibb; Dava Oncology; Dendreon; Janssen; Polaris; Valeant/Dendreon
Research Funding - AstraZeneca; Bristol-Myers Squibb; Janssen
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Compugen; Dava Oncology; Dendreon; Janssen; Parker Institute for Cancer Immunotherapy; Society for Immunotherapy of Cancer
 
Denai R. Milton
No Relationships to Disclose
 
Ana Aparicio
Honoraria - American Cancer Society; Amgen; Astellas Pharma; AstraZeneca; Biosense Webster (I); Boston Scientific (I); Daiichi Sankyo Inc; Janssen Research & Development
Consulting or Advisory Role - American Cancer Society; Amgen; Astellas Pharma; AstraZeneca; Biosense Webster (I); Boston Scientific (I); Daiichi Sankyo Inc.; Janssen Research & Development
Speakers' Bureau - Biosense Webster (I); Boston Scientific (I)
Research Funding - BioSense Webster (I); Boston Scientific (I); Bristol-Myers Squibb (Inst); Hansen Medical (I); Janssen (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Two (I)
Travel, Accommodations, Expenses - Biosense WEbster (I)
 
Timothy A. Yap
Employment - MD Anderson Cancer Center
Stock and Other Ownership Interests - Seagen
Consulting or Advisory Role - Abbvie; Acrivon Therapeutics; Adagene; Aduro Biotech; Almac Group; Amphista Therapeutics; Artios; AstraZeneca; Athenahealth; Atrin Pharmaceuticals; Avoro Capital Advisors; Axiom Biotechnologies; Baptist Health; Bayer; BeiGene; Boxer; Bristol-Myers Squibb; C4 Therapeutics; Calithera Biosciences; Cancer Research UK; Clovis Oncology; Cybrexa Therapeutics; Diffusion Pharmaceuticals; EMD Serono; F-Star; Genmab; Gerson Lehrman Group; GlaxoSmithKline; Glenmark; Globe Life Science; Guidepoint Global; Gustave Roussy Cancer Center; I-Mab; Idience; Ignyta; ImmuneSensor Therapeutics; Intellisphere; Janssen; Kyn therapeutics; MEI Pharma; Merck; Mereo BioPharma; Natera; Nexys Therapeutics; Novocure; OncoSec; Ono Pharmaceutical; Oregon Health & Science University (OHSU); Pegascy; PER; Pfizer; Piper Sandler; ProLynx; Repare Therapeutics; resTORbio; Roche; Schrodinger; Theragnostics; Varian Medical Systems; Versant Health; Vibliome Therapeutics; Xinthera; Zai Lab; ZielBio
Research Funding - Acrivon Therapeutics (Inst); Artios (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BioNTech (Inst); Blueprint Medicines (Inst); BMS (Inst); Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); Cyteir (Inst); EMD Serono (Inst); F-Star (Inst); Forbius (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Haihe Biopharma (Inst); ImmuneSensor Therapeutics (Inst); Ionis Pharmaceuticals (Inst); Ipsen (Inst); Jounce Therapeutics (Inst); Karyopharm Therapeutics (Inst); KSQ Therapeutics (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Ribon Therapeutics (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Scholar Rock (Inst); Seagen (Inst); Tesaro (Inst); Vivace Therapeutics (Inst); Zenith (Inst)
 
Aung Naing
Consulting or Advisory Role - CSL Behring (I); CytomX Therapeutics; Deka Biosciences; Genome & Company; Horizon Pharma (I); Kymab; Novartis; OncoSec; Pharming NV (I); STCube Pharmaceuticals Inc.; Takeda (I)
Research Funding - Amplimmune; Arcus Biosciences; ARMO BioSciences; Atterocor; Baxalta (I); BioNTech SE; Bristol-Myers Squibb; Calithera Biosciences; Chao Physician-Scientist Awards (I); CytomX Therapeutics; EMD Serono; Healios; Immune Deficiency Foundation (I); ImmuneOncia; Incyte; Jeffrey Modell Foundation (I); Karyopharm Therapeutics; Kymab; Lilly; MedImmune; Merck; Monopteros Therapeutics; NCI; NeoImmuneTech; Neon Therapeutics; Novartis; Pfizer; PsiOxus Therapeutics; Regeneron; Seven and Eight Biopharmaceuticals; Sotio; Surface Oncology; TopAlliance BioSciences Inc
Travel, Accommodations, Expenses - ARMO BioSciences
 
Paul Gettys Corn
Research Funding - Janssen Oncology (Inst)
 
Patrick Glen Pilié
Consulting or Advisory Role - Novartis
Patents, Royalties, Other Intellectual Property - Patent Pending- biomarker
 
Amado J. Zurita
Honoraria - Janssen; Pfizer
Consulting or Advisory Role - AstraZeneca; Bayer
Research Funding - Infinity Pharmaceuticals
 
Jennifer Wang
No Relationships to Disclose
 
Rodabe Navroze Amaria
Consulting or Advisory Role - Bristol-Myers Squibb/Medarex; Iovance Biotherapeutics; Nektar; Novartis; Obsidian Therapeutics
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); iovance Biotherapeutics (Inst); Merck (Inst); Novartis (Inst)
 
Jennifer Leigh McQuade
Honoraria - Bristol-Myers Squibb/Roche; Merck
Consulting or Advisory Role - Bristol Myer Squibb; Roche Pharma AG
Travel, Accommodations, Expenses - Merck
 
Isabella Claudia Glitza
Honoraria - Amgen
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Novartis
Speakers' Bureau - Array BioPharma
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst); Pfizer
 
Alexander J. Lazar
Leadership - Archer; Iterion Therapeutics; Nucleai
Stock and Other Ownership Interests - Archer; Beta Cat Pharmaceuticals; PAIGE.AI
Honoraria - Bristol-Myers Squibb; Genentech/Roche; Janssen Oncology; Novartis
Consulting or Advisory Role - Abbvie; Bayer; BMS; Deciphera; Novartis
Research Funding - AstraZeneca; MedImmune; Novartis; Roche
Patents, Royalties, Other Intellectual Property - Elsevier
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
 
Funda Meric-Bernstam
Employment - MD Anderson Cancer Center
Consulting or Advisory Role - Abbvie; AstraZeneca; Biovica; Black Diamond Therapeutics; Debiopharm Group; eFFECTOR Therapeutics; Eisai; Infinity Pharmaceuticals; Karyopharm Therapeutics; Kolon Life Sciences; Lengo Therapeutics; Loxo; OnCusp Therapeutics; PACT Pharma; Roche; Seagen; Silverback Therapeutics; Tallac Therapeutics; Tyra Biosciences; Xencor; Zentalis; Zymeworks
Research Funding - Abbvie (Inst); Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); eFFECTOR Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Guardant Health (Inst); Jounce Therapeutics (Inst); Klus Pharma (Inst); Novartis (Inst); Pfizer (Inst); PUMA Biotechnology (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Zymeworks (Inst)
 
Christopher Logothetis
Honoraria - Amgen; Bayer; Merck Sharp & Dohme
Consulting or Advisory Role - Amgen; Bayer; Exelixis; Merck Sharp & Dohme
Research Funding - Aragon Pharmaceuticals (Inst); Janssen; Novartis; ORIC Pharmaceuticals (Inst)
 
Michael A. Davies
Consulting or Advisory Role - ABM; Apexigen; Array BioPharma; Bristol-Myers Squibb; Eisai; Genentech/Roche; NanoString Technologies; Novartis; Pfizer
Research Funding - AstraZeneca (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Myriad Genetics (Inst); Oncothyreon (Inst); Pfizer (Inst); Sanofi (Inst)
 
Patrick Hwu
Stock and Other Ownership Interests - Dragonfly Therapeutics; Immatics
Consulting or Advisory Role - Dragonfly Therapeutics; Immatics
Research Funding - Genentech (Inst)
 
Hussein A. Tawbi
Consulting or Advisory Role - Array BioPharma; Boxer Capital; Bristol-Myers Squibb; Eisai; Genentech/Roche; Iovance Biotherapeutics; Jazz Pharmaceuticals; Karyopharm Therapeutics; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Dragonfly Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); RAPT Therapeutics (Inst)